Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index; 26 of the 33 sources its claims cite were checked for support.

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Open access

Abstract

Aims: The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2 diabetes and chronic kidney disease (CKD) examined cardiovascular and kidney outcomes in different, overlapping stages of CKD. The purpose of the FIDELITY analysis was to perform an individual patient-level prespecified pooled efficacy and safety analysis across a broad spectrum of CKD to provide more robust estimates of safety and efficacy of finerenone compared with placebo. Methods and results: For this prespecified analysis, two phase III, multicentre, double-blind trials involving patients with CKD and type 2 diabetes, randomized 1:1 to finerenone or placebo, were combined. Main time-to-event efficacy outcomes were a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure, and a composite of kidney failure, a sustained ≥57% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death. Among 13 026 patients with a median follow-up of 3.0 years (interquartile range 2.3–3.8 years), the composite cardiovascular outcome occurred in 825 (12.7%) patients receiving finerenone and 939 (14.4%) receiving placebo [hazard ratio (HR), 0.86; 95% confidence interval (CI), 0.78–0.95; P = 0.0018]. The composite kidney outcome occurred in 360 (5.5%) patients receiving finerenone and 465 (7.1%) receiving placebo (HR, 0.77; 95% CI, 0.67–0.88; P = 0.0002). Overall safety outcomes were generally similar between treatment arms. Hyperkalaemia leading to permanent treatment discontinuation occurred more frequently in patients receiving finerenone (1.7%) than placebo (0.6%). Conclusion: Finerenone reduced the risk of clinically important cardiovascular and kidney outcomes vs. placebo across the spectrum of CKD in patients with type 2 diabetes. Key Question: Does finerenone, a novel selective, nonsteroidal mineralocorticoid receptor antagonist, added to maximum tolerated renin–angiotensin system inhibition reduce cardiovascular disease and kidney disease progression over a broad range of chronic kidney disease in patients with type 2 diabetes? Key Finding: In a prespecified, pooled individual-level analysis from two randomized trials, we found reductions both in cardiovascular events and kidney failure outcomes with finerenone. Because 40% of the patients had an estimated glomerular filtration rate of >60 mL/min/1.73m2 they were identified solely on the basis of albuminuria. Take Home Message: Finerenone reduces the risk of clinical cardiovascular outcomes and kidney disease progression in a broad range of patients with chronic kidney disease and type 2 diabetes. Screening for albuminuria to identify at-risk patients among patients with type 2 diabetes facilitates reduction of both cardiovascular and kidney disease burden.

Overview

CoChat Summary

TL;DR

In a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD (13,026 patients with type 2 diabetes and CKD), finerenone reduced composite cardiovascular and kidney outcomes versus placebo. Hyperkalaemia was more frequent with finerenone but rarely led to permanent discontinuation, and no fatal hyperkalaemia occurred.

Key findings

  • The composite cardiovascular outcome (cardiovascular death, non-fatal MI, non-fatal stroke, or hospitalization for heart failure) occurred in 825 (12.7%) finerenone patients vs 939 (14.4%) placebo patients (HR 0.86; 95% CI 0.78–0.95; P=0.0018).
  • The composite kidney outcome (kidney failure, sustained ≥57% eGFR decrease over ≥4 weeks, or renal death) occurred in 360 (5.5%) finerenone patients vs 465 (7.1%) placebo patients (HR 0.77; 95% CI 0.67–0.88; P=0.0002).
  • Hospitalization for heart failure was lower with finerenone (HR 0.78; 95% CI 0.66–0.92; P=0.0030); sustained ≥57% eGFR decrease had HR 0.70 (95% CI 0.60–0.83; P<0.0001) and ESKD had HR 0.80 (95% CI 0.64–0.99; P=0.040).
  • Hyperkalaemia leading to permanent treatment discontinuation occurred in 1.7% of finerenone patients vs 0.6% of placebo patients; hyperkalaemia-related adverse events occurred in 14.0% vs 6.9%, with no fatal hyperkalaemia.

Methods

  • Prespecified pooled individual patient-level analysis of two phase III, multicentre, double-blind, placebo-controlled trials (FIDELIO-DKD and FIGARO-DKD) in adults with type 2 diabetes and CKD on maximum tolerated ACEi or ARB, randomized 1:1 to finerenone or placebo.
  • The full analysis set included 13,026 patients after prospective exclusion of 145 patients with critical Good Clinical Practice violations; median follow-up was 3.0 years (IQR 2.3–3.8), mean eGFR was 57.6 mL/min/1.73 m², and median UACR was 515 mg/g.
  • Outcomes were analyzed with stratified Cox proportional hazards models using stratification factors including study, region, eGFR category, albuminuria category, and history of cardiovascular disease; P-values came from stratified log-rank tests, and analyses were prespecified exploratory without multiplicity adjustment.

Limitations

  • Stated in the paper: the analysis did not include patients with non-albuminuric CKD, and only a small proportion of Black patients were included.
  • Stated in the paper: SGLT-2 inhibitors emerged as therapeutic options after the trials were designed; some patients received these agents at baseline, and combination efficacy/safety was not tested in a randomized combination trial.
  • Evident from the text: statistical tests were exploratory rather than hypothesis-confirming and no multiplicity adjustment was performed; patients with chronic symptomatic heart failure with reduced ejection fraction were excluded, limiting generalizability to that population.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab777

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Structured Graphical Abstract Finerenone reduced the risk of clinically important cardiovascular and kidney outcomes versus placebo across the spectrum of chronic kidney disease in patients with type 2 diabetes.
Structured Graphical Abstract Finerenone reduced the risk of clinically important cardiovascular and kidney outcomes versus placebo across the spectrum of chronic kidney disease in patients with type 2 diabetes.CC BY-NC · PubMed Central
Figure 1 Time to efficacy outcomes. (A) The composite cardiovascular outcome defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure (Aalen–Johansen curve). (B) The composite kidney outcome defined as kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death (Aalen–Johansen curve). (C) The composite kidney outcome defined as kidney failure, sustained ≥40% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death (Aalen–Johansen curve). (D) All-cause mortality (Kaplan–Meier curve). Outcomes were assessed in time-to-event analyses.
Figure 1 Time to efficacy outcomes. (A) The composite cardiovascular outcome defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure (Aalen–Johansen curve). (B) The composite kidney outcome defined as kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death (Aalen–Johansen curve). (C) The composite kidney outcome defined as kidney failure, sustained ≥40% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death (Aalen–Johansen curve). (D) All-cause mortality (Kaplan–Meier curve). Outcomes were assessed in time-to-event analyses.CC BY-NC · PubMed Central
Figure 2 Efficacy outcomes. aStatistical tests where P-values are provided were exploratory in nature; therefore, no adjustment for multiplicity was performed. bThe composite of time to first onset of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure. cThe composite of time to first onset of kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death. dInitiation of chronic dialysis for ≥90 days or kidney transplantation. eAnalyses for P-values not prespecified. fThe composite of time to first onset of kidney failure, sustained ≥40% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death. g P = 1.001 to 3 decimal places.
Figure 2 Efficacy outcomes. aStatistical tests where P-values are provided were exploratory in nature; therefore, no adjustment for multiplicity was performed. bThe composite of time to first onset of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure. cThe composite of time to first onset of kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death. dInitiation of chronic dialysis for ≥90 days or kidney transplantation. eAnalyses for P-values not prespecified. fThe composite of time to first onset of kidney failure, sustained ≥40% decrease in estimated glomerular filtration rate from baseline over ≥4 weeks, or renal death. g P = 1.001 to 3 decimal places.CC BY-NC · PubMed Central
Figure 3 Components of the composite cardiovascular outcome. Outcomes were assessed in time-to-event analyses (Aalen–Johansen curves). (A) Cardiovascular death. (B) Non-fatal myocardial infarction. (C) Non-fatal stroke. (D) Hospitalization for heart failure.
Figure 3 Components of the composite cardiovascular outcome. Outcomes were assessed in time-to-event analyses (Aalen–Johansen curves). (A) Cardiovascular death. (B) Non-fatal myocardial infarction. (C) Non-fatal stroke. (D) Hospitalization for heart failure.CC BY-NC · PubMed Central

Verification

Claims the paper makes

14 Valid · 2 Not valid · 2 Not checked · 76 Own results and interpretations

55 more claims · 5 with their cited sources checked

Create a free account to see all 94 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 17
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

23 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 31 references

Cited by

See all 1,317

Metadata

Authors
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., Bakris, G. L., & FIDELIO-DKD and FIGARO-DKD investigators
Affiliations
  • Richard L. Roudebush VA Medical Center (US)
  • University General Hospital Attikon (GR)
  • University of Michigan (US)
  • German Centre for Cardiovascular Research (DE)
  • University of Copenhagen (DK)
  • Bayer (Germany) (DE)
  • Research Institute Hospital 12 de Octubre (ES)
  • University of Chicago (US)
Corresponding author
  • Agarwal, Rajiv
  • Filippatos, Gerasimos
Venue
European Heart Journal
Published
2021-11-22
Volume
43
Issue
6
Pages
474-484
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4206077470
Cited by
1,317
References
31
Citations by year
2026: 340 · 2025: 348 · 2024: 265 · 2023: 243 · 2022: 115 · 2021: 4
FWCI
107.33
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by-nc)
  • ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, cc-by-nc)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
Funders
Bayer AG,
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
finerenone, type 2 diabetes, chronic kidney disease, mineralocorticoid receptor antagonists, cardiovascular outcomes, renal outcomes, hyperkalemia, renin-angiotensin system blockade, FIDELIO-DKD, FIGARO-DKD, heart failure hospitalization, renal failure, estimated glomerular filtration rate decline, renal safety
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Kidney, Naphthyridines, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. https://app.cochat.ai/papers/10.1093/eurheartj/ehab777
The paper
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., Bakris, G. L., & FIDELIO-DKD and FIGARO-DKD investigators. (2022). Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab777

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.